Disclosed herein are benzofuran compounds of general formula (C), wherein the substituents are as defined within the specification, processes for their preparation, compositions comprising said compounds and uses thereof. Said compounds are useful as GPR120 agonists (gastrin releasing peptide), as such are useful in the treatment of Type I or II diabetes and metabolic syndrome. Examples of particularly preferred compounds include: 3-(2,6-difluoro-4-((5-fluoro-2,2-dimethyl-2,3-dihydrobenzofuran-7-yl)methoxy)phenyl)propanoic acid 3-(2-bromo-4-((5-chloro-2,2-dimethyl-2,3-dihydrobenzofuran-7-yl)methoxy)-5-methoxvphenyl)propanoic acid 3-(4-((5-(3-chlorophenyl)-2,2-dimethyl-2,3-dihydrobenzofuran-7-yl)methoxy)phenyl)-2-methylpropanoic acid 2-(4-((5-fluoro-2,2-dimethyl-2,3-dihydrobenzofuran-7-yl)methoxy)phenyl)cyclopropanecarboxylic acid 3-(4-((5-chloro-2,2-dimethyI-2,3-dihydrobenzofuran-7-yl)methoxy)-2-(trifluoromethoxy)phenyI)propanoic acid.
